AdegokeA, GladneyK, GallantM, et al.Heteroclitic Peptides Increase Proliferation and Reduce Evidence of Human Immunodeficiency Virus-Specific CD8(+) T Cell Dysfunction. Viral Immunol, 2015; 28:455–463. doi: 10.1089/vim.2015.0036.
2.
GambergJ, BarrettL, BowmerMI, et al.Factors related to loss of HIV-specific cytotoxic T lymphocyte activity. AIDS, 2004a;18:597–604. doi: 10.1097/00002030-200403050-00003.
3.
GambergJ, PardoeI, BowmerMI, et al.Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol Cell Biol, 2004b;82:38–46. doi: 10.1111/j.1440-1711.2004.01204.x.
4.
GambergJC, BowmerMI, TraheyJC, et al.Functional and genetic integrity of the CD8 T-cell repertoire in advanced HIV infection. AIDS, 1999; 13:2043–2053. doi: 10.1097/00002030-199910220-00006.
5.
HolderKA, BurtK, GrantMD. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4(+) T cells. Clin Transl Immunol, 2021; 10:e1348. doi: 10.1002/cti2.1348. eCollection 2021.
6.
KellyD, BurtK, MissaghiB, et al.Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals. BMC Immunol, 2012; 13:49. doi: 10.1186/1471-2172-13-49.
7.
KottililS, BowmerMI, TraheyJ, et al.Fas/FasL-independent activation-induced cell death of T lymphocytes from HIV-infected individuals occurs without DNA fragmentation. Cell Immunol, 2001; 214:1–11. doi: 10.1006/cimm.2001.1876.
8.
KottililS, GambergJ, BowmerI, et al.Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells. J Clin Immunol, 2000; 20:175–186. doi: 10.1023/a:1006633429087.
9.
MasonRD, BowmerMI, HowleyCM, et al.Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol, 2004; 172:7212–7219. doi: 10.4049/jimmunol.172.11.7212.
10.
RussellRR, BowmerMI, NguyenC, et al.HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. Viral Immunol, 2001; 14:379–389. doi: 10.1089/08828240152716628.
